Clinical Research Directory

Inclusion Criteria: * History of unilateral supratentorial ischemic, intracerebral hemorrhagic, subarachnoid hemorrhagic, or a heterogeneous lesion stroke that occurred at least 6 months but not more than 15 years prior to enrollment. * Age \>30 years and \<85 years. * Fugl-Meyer Assessment, Upper Limb (FMA-UE) baseline score of 10 to 56 (inclusive of 10 and 56). * Ability to communicate, understand, and provide appropriate consent. Subjects should be able to follow two-step commands. * Right- or left-sided weakness of the upper extremity. Exclusion Criteria * Participant with any implanted metallic device at or near the stimulation sites (forehead and ears). * Participant with an implanted or active stimulator (ex. Deep brain stimulator, pacemaker, vagus nerve stimulator, defibrillator) * Participant skin in the stimulation area has open wounds, skin eruptions, swollen, infected, or inflamed areas, or skin abnormalities that could be cancerous * Advanced cardiac, pulmonary, liver, kidney dysfunction or blood system disease * Participant has a fever or shows clinical signs concerning for an infectious disease * Other neurologic or musculoskeletal diseases that could interfere with the assessments of this study * Low heart rate (\<60 bpm) from a cardiac conduction block or related etiology * Participant has a history of trigeminal neuralgia * Participant has a history of Bell's Palsy * History of cranial nerve neuropathy (including facial nerve injury), carotid surgery, vagotomy, or other surgical intervention on the vagus nerve * History of recurrent syncopal events * Known or newly-discovered aneurysm or arteriovenous malformation * Patients who have any terminal illness such that the patient would not be expected to survive more than 90 days * Botox injections 12 weeks prior to or during therapy * Participants who have had a craniectomy: * Without replacement of bone flap * With bone flap replaced \< 6 months prior to initiation of study activities